74%
de las cuentas minoristas pierden dinero al operar CFDs con este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierden dinero cuando operan con CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs, y si puedes permitirte asumir el alto riesgo de perder tu dinero.
74%
de las cuentas minoristas pierden dinero al operar CFDs con este proveedor.
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
74%
de inversores minoristas pierden dinero cuando operan con CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs, y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Español (Latinoamérica)
Sanofi SA
Cerrado
SectorSalud
92.54 -0.88
Resumen
Variación precio
24h
Mínimo
92.18
Máximo
94.26
Ingresos | -2.3B 499M |
|---|---|
Ventas | -6.5B 7.6B |
P/B Media del Sector | 20.663 57.333 |
BPA | 1.31 |
Rentabilidad por dividendo | 4.32 |
Margen de beneficio | 6.539 |
Empleados | 82,878 |
EBITDA | -3.7B 563M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +22.28% upside |
Rentabilidad por dividendo Media del Sector | 4.32% 2.63% |
|---|
Capitalización de Mercado | -20B 111B |
|---|---|
Apertura anterior | 93.42 |
Cierre anterior | 92.54 |
Puntuación técnica
By Trading Central
Confianza
Neutral Evidence
Sanofi SA Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Sanofi SA Esperado
Precio Objetivo
By TipRanks
22.28% repunte
Estimación a 12 meses
Media 114.144 EUR 22.28%
Máximo 127 EUR
Mínimo 83.729 EUR
De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Sanofi SA
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
